Table 3.
Correlation analysis of the effects of candidate risk factors on microangiopathy in patients with epilepsy and controls.
| Urine albumin/creatinine ratio |
Retinal vein diameter |
|||
|---|---|---|---|---|
| Variables | Correlation coefficient | p Value | Correlation coefficient | p Value |
| Age | −0.080 | 0.195 | −0.221* | 0.008 |
| Body mass index | 0.058 | 0.266 | 0.055 | 0.277 |
| Duration of AED therapy | 0.030 | 0.374 | −0.250* | 0.003 |
| EIAEDs | −0.162* | 0.040 | 0.155* | 0.047 |
| Duration of EIAED therapy | 0.080 | 0.193 | −0.327* | 0.001 |
| Duration of non-EIAED therapy | −0.085 | 0.179 | −0.034 | 0.359 |
| AED number | 0.040 | 0.333 | −0.020 | 0.416 |
| Homocysteine | 0.004 | 0.482 | 0.109 | 0.119 |
| hs-CRP | 0.206* | 0.013 | 0.037 | 0.345 |
| Total cholesterol | 0.217* | 0.009 | −0.027 | 0.386 |
| LDL-C | 0.167* | 0.036 | 0.045 | 0.315 |
| Triglyceride | 0.313* | 0.001 | 0.083 | 0.187 |
| Glycated hemoglobin (HbA1c) | 0.084 | 0.182 | −0.021 | 0.410 |
| Creatinine | −0.044 | 0.318 | 0.272* | 0.001 |
AED, antiepileptic drug, EIAEDs, enzyme-inducing antiepileptic drugs, hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index.
The duration of AED therapy was considered 0 in the control group.
*p < 0.05.